ClinicalTrials.gg
CompletedNCT05231044Updated Apr 19, 2024

A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp

A Phase 3 interventional study of KX01 ointment 1% and Placebo in Actinic Keratosis, sponsored by PharmaEssentia. Completed at 20 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by PharmaEssentia · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This Phase III study is designed to evaluate the efficacy and safety of KX01 Ointment in adult participants when applied to an area of skin containing more than 1, clinically typical Actinic Keratosis (AK) lesions on the face or scalp.

Read the detailed description

This study is a double-blinded, multicenter, activity, and safety study of KX01 Ointment administered topically to the face or scalp of participants with actinic keratosis. The study consists of Screening, Treatment, Follow-up, and Recurrence Follow-up Periods. Eligible participants received 5 consecutive days of topical treatment, to be applied at the study site. Activity (lesion counts) and safety evaluations is performed.

02

Conditions studied

  • Actinic Keratosis

Keywords

  • Actinic Keratosis
  • Skin disease
03

In context

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

This study's enrollment of 108 is above the median of 60 across 295 interventional studies indexed under Keratosis, Actinic.

Browse Keratosis, Actinic studies →

Lead sponsor

PharmaEssentia is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese Males and females ≥20 years old
  2. A treatment area on the face or scalp that:

    1. is a contiguous area measured 25 cm2
    2. contains more than 1 clinically typical, visible, and discrete AK lesions
  3. Subjects who, in the judgment of the Investigator or Sub-investigator, are in good general health based on:

    1. medical history
    2. physical examination (PE) findings
    3. vital signs
    4. clinical chemistry, hematology, and urinalysis results
  4. Females must be (>45 years of age with at least 12 months of amenorrhea), surgically sterile (by hysterectomy, bilateral oophorectomy, or tubal ligation); or, women with must use highly effective for at least 30 days or 1 menstrual cycle, whichever is longer, prior to study treatment and must agree to continue to use highly effective contraception for at least 30 days following their last dose of study treatment. Highly effective contraception includes oral hormonal contraceptives, hormonal contraceptive implant, injection or patch, intrauterine device, or complete abstinence from sexual intercourse.
  5. Sexually active males who have not had a vasectomy and whose partner is reproductively capable must agree to use barrier contraception from Screening until 90 days after their last dose of study treatment.
  6. All subjects must agree not to donate sperm or eggs or attempt conception from Screening until 90 days following their last dose of study treatment.
  7. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 prior to randomization.
  8. Willing to avoid excessive sunlight or ultraviolet (UV) light exposure, including the use of tanning beds, to the face or scalp

Exclusion criteria

Exclusion Criteria:

  1. Clinically atypical and / or rapidly changing AK lesions on the treatment area, e.g., hypertrophic, hyperkeratotic, recalcitrant disease (had cryosurgery on two previous occasions) and / or cutaneous horn
  2. Location of the treatment area is:

    • On any location other than the face or scalp
    • Within 5 cm of an incompletely healed wound
    • Within 5 cm of a suspected basal cell carcinoma (BCC) or SCC
  3. Been previously treated with KX01 Ointment
  4. Anticipated need for in-patient hospitalization or in-patient surgery from Day 1 to Day 57
  5. Treatment with 5-fluorouracil (5-FU), imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other treatments for AK within the treatment area or within 2 cm of the treatment area, within 8 weeks prior to the Screening visit
  6. Use of the following therapies and / or medications within 2 weeks prior to the Screening visit:

    • Cosmetic or therapeutic procedures (e.g., use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing) within the treatment area or within 2 cm of the selected treatment area
    • Acid-containing therapeutic products (e.g., salicylic acid or fruit acids, such as alpha- and beta-hydroxyl acids and glycolic acids), topical retinoids, or light chemical peels within the treatment area or within 2 cm of the selected treatment area
    • Topical salves (non-medicated / non-irritant lotion and cream are acceptable) or topical within the treatment area or within 2 cm of the selected treatment area; artificial tanners within the treatment area or within 5 cm of the selected treatment area
  7. Use of the following therapies and / or medications within 4 weeks prior to the Screening visit:

    • Treatment with immunomodulators (e.g., azathioprine), cytotoxic drugs (e.g., cyclophosphamide, vinblastine, chlorambucil, methotrexate), or interferons / interferon inducers
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    KX01 Ointment 1%

    KX01 Ointment 1% is applied topically once daily for 5 consecutive days on face or scalp

    Drug: KX01 ointment 1%

  • Placebo comparator
    Placebo

    Vehicle Ointment is applied topically once daily for 5 consecutive days on face or scalp

    Drug: Placebo

Interventions

  • The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.

  • DrugPlacebo

    Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with complete (100%) clearance of Actinic Keratosis (AK) lesions

    Complete clearance rate is defined as the percentage of participants at Day 57 with no clinically visible AK lesions in the treatment area.

    Time frame: Day 57

Secondary outcomes

  1. Partial Clearance Rate of AK Lesions at Day 57

    Partial clearance rate of AK lesions is defined as the proportion of subjects on Day 57 with a ≥ 75% reduction in the number of AK lesions identified at Baseline (Day 1 predose) in the treatment area.

    Time frame: Day 57

  2. Recurrence rate of AK lesions in subjects who achieved complete clearance at Day 57

    For subjects who achieve 100% clearance of AK lesions in the treatment area on Day 57, a Investigator or Sub-investigator will perform a count of clinically visible AK lesions (lesion count) during the Recurrence Follow-up Period at the 3-, 6-, 9- and 12-month visits. In principle, the Investigator or Sub-investigator performing the lesion count should be the same Investigator or Sub-investigator who evaluated the subject previously during the study.

    Time frame: 3, 6, 9 and 12 months post-Day 57

  3. Number of participants with local skin reactions (LSR) in the treatment area

    At Baseline (Day 1 predose), LSRs on the treatment area will be assessed by the Investigator or Sub-investigator. The same Investigator or Sub-investigator will conduct the LSR assessment at all visits for an individual subject. LSR signs on the treatment area include the following: erythema, flaking / scaling, crusting, swelling, vesiculation / pustulation, and erosion / ulceration. These signs will be assessed using a 4-point grading scale.

    Time frame: Baseline (Day 1 predose), Days 5, 8, 15, 29 and 57

  4. Number of participants with pigmentation and scarring in the treatment area

    At the time of LSR assessment, hypo- and hyper-pigmentation and scarring on the treatment area will be assessed by the Investigator or Sub-investigator as being present or absent. Pigmentation and scarring will be assessed at Baseline (Day 1 predose). In principle, the same Investigator or Sub-investigator will assess pigmentation and scarring at all visits for an individual subject.

    Time frame: Baseline (Day 1 predose), Days 5, 8, 15, 29 and 57

  5. Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs), events of special interest

    Time frame: From Baseline (Day 1 predose) up to Day 57

  6. Number of participants with AEs within the treatment area after Day 57 up to 12 months post-Day 57

    Time frame: After Day 57 up to 12 months post-Day 57

07

Study locations

20 sites
  • Toho University Medical Center Sakura Hospital
    Chiba, Japan
  • Kiryu Dermatology Clinic
    Fukuoka, Japan
  • Tomoko Matsuda dermatology Clinic
    Fukuoka, Japan
  • Takamatsu Red Cross Hospital
    Kagawa, Japan
  • Hashiguchi Dermatology
    Kagoshima, Japan
  • Katahira Dermatology and Urology
    Kagoshima, Japan
  • National Hospital Organization Sagamihara National Hospital
    Kanagawa, Japan
  • Nippon Medical School Musashi Kosugi Hospital
    Kanagawa, Japan
  • Kumamoto University Hospital
    Kumamoto, Japan
  • Noguchi Dermatology Clinic
    Kumamoto, Japan
  • Suizenji Dermatology Clinic
    Kumamoto, Japan
  • Futaba Dermatology and Skin Surgery Clinic
    Miyazaki, Japan
  • Toyama Hifuka
    Miyazaki, Japan
  • Okayama Saiseikai Outpatient Center Hospital
    Okayama, Japan
  • Medical Corporation Ayumi Sakurakai Dermatology Ophthalmology Kume Clinic
    Osaka, Japan
  • Mochidahifuka
    Osaka, Japan
  • Juntendo University Hospital
    Tokyo, Japan
  • NTT Medical Center Tokyo
    Tokyo, Japan
  • Toyama Prefectural Central Hospital
    Toyama, Japan
  • University of Yamanashi Hospital
    Yamanashi, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Nov 2023, 22 months.

Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Feb 9, 2022
StartActual
Dec 21, 2021
Primary completionActual
Nov 20, 2023
CompletionActual
Nov 20, 2023
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05231044
Lead sponsor
PharmaEssentia
Collaborators
PharmaEssentia Japan K.K.
Responsible party
Sponsor
First posted
Feb 9, 2022
Start date
Dec 21, 2021
Primary completion
Nov 20, 2023
Completion
Nov 20, 2023
Last update
Apr 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirbanibulin

Start the discussion